Table 3.
Multivariate analysis of overall survival in immunotherapy cohorts
| Characteristic | Discovery Cohort | Validation Cohort | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Pretreatment eosinophil count, Eos-Lo vs Eos-Hi (reference) | 3.23 | 1.42–7.38 | 0.005 | 2.32 | 1.20–4.48 | 0.012 |
| DDR status, DDRmut (deleterious + VUS) vs DDRwt | 0.37 | 0.18–0.75 | 0.006 | 0.82 | 0.46–1.46 | 0.510 |
| Bellmunt prognostic factors a | ||||||
| 1 vs 0 | 1.10 | 0.40–3.02 | 0.860 | 1.25 | 0.59–2.64 | 0.567 |
| 2 or 3 vs 0 | 1.43 | 0.48–4.29 | 0.524 | 2.53 | 1.11–5.80 | 0.028 |
a
Presence of liver metastasis, hemoglobin level of less than 10 g/dL, and ECOG performance status of more than zero.
Abbreviations: DDR, DNA damage repair; DDRmut, any mutation in DDR; DDRwt, wild-type DDR